suPARnostic® provides improved risk stratification of patients in the emergency department.

Eliminate doubt in clinical decisions

Using suPAR in clinical care allows healthcare professionals to identify and discharge more patients, reducing stress, crowding, and healthcare costs. Earlier Identification of high-risk patients can provide faster clinical intervention and better patient outcomes.

suPARnostic® is the only CE-IVD certified product range applied for clinical measurement of suPAR in human plasma and serum. It enables healthcare professionals to make fast clinical decisions based on prognostic evidence across diseases.

A low suPAR level (under 4 ng/ml) indicates a good prognosis and supports the decision to discharge the patient.

A high suPAR level (over 6 ng/ml) indicates the presence, progression, and severity of disease, organ damage, mortality risk and supports further clinical attention.

How to interpret suPAR results

Documented by 700+ peer-reviewed publications

Here you can find a summary of the research done on suPAR within different disease areas.

Drawing of People and a hospital bed

Achieve significant healthcare cost savings

In emergency departments and hospital wards, suPARnostic® can identify low-risk patients, resulting in earlier and safer discharges. A study examining the effectiveness of using suPAR as a risk stratification tool showed that hospitals could save one bed for 24 hours in every four patients admitted.*

*Schultz et al. Disease Markers, 2019, 10;1-8A sub study of the interventional TRIAGE III trial, comparing patients with a valid suPAR measurement at admission to those without in EDs at two university hospitals in the Capital Region of Denmark.

“The key challenge for the emergency department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”

MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen

Early anakinra treatment of COVID-19 patients guided by suPAR saves lives

Get our whitepaper about the study results and read more about how an early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.


published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex


For Automated Systems

Photo of suPARnostic® ELISA


Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates